The global market for ketamine products, particularly for therapeutic use in mental health treatment, is rapidly expanding. The market size was valued at around $2.5B in 2023 and is projected to reach $10.3B by 2032, growing at a compound annual growth rate (CAGR) of 16.8%. This growth is driven by ketamine’s effectiveness in treating conditions like depression, PTSD, and chronic pain. The therapeutic use of ketamine has the potential to significantly decrease healthcare costs.